Biogen Inc BIIB

Razak_Yorou

According to MarketWatch, The FDA approved the Alzheimer's drug Legembi from Eisai and Biogen A quick look at the daily charts for $BIIB shows that it's already trading on or above major moving averages (ie. 9,21,50 SMA's). Also, seeing as this is a nice, green day for the SPY and BIIB has been beaten down recently, it's a nice long option for medium term traders...

PlanTradePlanMM Pro Updated 

In downtrend, bounced back to Supply zone Current Monthly chart price range 73 - 217 Earning 7/26/2022 Estimate 4.09 Short 200 Stop 220 Target 140 Risk management is much more important than a good entry point. I am not a PRO trader. In my trading plan, the Max Risk of each short term trade should be less than 1% of an account.

MishkaLA Premium Updated 

Order SELL BIIB NASDAQ.NMS Stop 278.12 LMT 278.12 will be automatically canceled at 20230401 01:00:00 EST BIIB daily bearish hammer end of wave 5 expect correction at the very least

EPSMomentum Premium

The PEAD projected a Neutral outlook for $BIIB after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 75%.

MishkaLA Premium Updated 

Order SELL BIIB NASDAQ.NMS Stop 249.27 LMT 249.27 will be automatically canceled at 20230401 01:00:00 EST BIIB daily bearish hammer

EPSMomentum Premium

The PEAD projected a Bearish outlook for $BIIB after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 100%.

Trusting-Miracles Premium

Journal Entry Bias: Positive. Sentiment: Optimistic. Emoji (emotion): Speculative 🧙‍♂️. Null Hypothesis: Buy. Alternative Hypothesis: Sell, Buy then Sell. Signals: ... Position: Day/Swing trade. Notes: I'm anticipating the market to buy the earnings surprise 07/20/22 BMO: www.estimize.com Barron's Company Overview: www.barrons.com . Other:...

TopgOptions Premium

Looking at the options chain today, i would buy the $255 calls with 2022-9-16 expiration date for about $3.40 premium. Looking forward to read your opinion about it.

Trader_Danny_ Updated 

possible long for biib, in a long term buy zone now with it breaking over descending resistance after a double bottom

Bixley

My recent post was a bearish view for BIIB, it included some Fibonacci Circles and I am questioning my ability to plot these. So I have posted a much simpler chart that shows a dominant trend line in green that should be maintained Once the descending channel reaches this level price should move upwards. Here is the bear view

Peet_Serfontein Premium

Remains a very risky trade. A falling wedge pattern might be developing. The break usually occurs to the upside. Above 190.00 supports a bullish trend direction. Crossing below this level will negate the positive stance. Further bullish support for a price action above 197.50. Consolidation is between 193.75 and 201.25. Crossing above 201.25 might target...

EPSMomentum Premium

The PEAD projected a Bullish outlook for $BIIB after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 87.5%.

Bixley

Repeating structure in green rectangle Continuing the up channel Red horizontals are the very similar points just on different magnitudes

Fomenka

This (C) may not be finished yet but the overall picture looks seductive enough to park some cash in anticipation of the bounce.

chinawildman Pro

Coiling and looks to be painting a 5 wave C here. About to tap 200 MONTH MA and a lifetime .618 retrace to end wave II to start a potentially massive wave III. Will potentially trade all the way down to 140s but am going to start nibbling here for a lifetime HODL.

loxx Premium Updated 

BIIB Continuation LONG. TPs and SL on the chart. Max leverage.

inferno32

We're getting close the descending wedge and we're touching multi-year support at around 205. $BIIB has been in a downtrend since June with no signs of life so we could see a bounce or breakdown to lower lows.

lucasschnare1

The basics: Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. I expect this industry to continue to grow as new advancements are made. Trade Idea: Since September of 2013 Biogen...